S
Sapreme Technologie
Develops new technologies within the field of macromolecule therapeutics such as antibody-drug conjugates and oligonucleotide-based therapeutics
About Sapreme Technologie
Sapreme Technologies is a cutting-edge biotech startup focused on overcoming a significant challenge in drug delivery known as endolysosomal trapping. This issue occurs when therapeutic macromolecules, such as RNA-based drugs, get trapped in cellular compartments called endosomes and lysosomes, preventing them from reaching their intended targets within cells. Sapreme's proprietary Endosomal Escape Platform aims to solve this problem, thereby enhancing the effectiveness of next-generation macromolecule therapeutics.
The company primarily serves pharmaceutical and biotechnology firms that are developing advanced therapies, including RNA-based treatments. These clients are looking for innovative solutions to improve the delivery and efficacy of their therapeutic products. Sapreme operates in the highly specialized and rapidly growing market of drug delivery technologies, which is a crucial segment of the broader pharmaceutical and biotech industries.
Sapreme's business model revolves around the development and licensing of its proprietary technology. The company generates revenue by partnering with pharmaceutical and biotech companies, who pay for access to Sapreme's platform to enhance their own drug development efforts. Additionally, Sapreme may engage in collaborative research and development projects, further diversifying its income streams.
In summary, Sapreme Technologies is a biotech innovator addressing a critical bottleneck in drug delivery. By enabling more effective delivery of macromolecule therapeutics, the company is poised to make a significant impact on the pharmaceutical and biotech industries.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Driebergen-Rijsenburg, Netherlands
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 75.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2021 | $17M | $66M | Aglaia BioMedical Ventures | — |
Growth signals
Latest recorded traffic for Sapreme Technologie is 290 monthly website visits, up 20.8% over the last three months. Sapreme Technologie's team grew 7.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Aglaia BioMedical Ventures
Other known investors1 additional known investor
Karl Rothweiler
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sapreme Technologie on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sapreme Technologie’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.